Market research
BAFNAPH.NSE Bafna Pharmaceuticals Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 10B
- P/E ratio
- 134.64
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.07
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE878I01022
- Market cap
- 10B
- P/E ratio
- 134.64
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.07
About
About Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company offers its products in various dosage forms, including tablets, capsules, and solid orals. It provides various products for cardiovascular and hypertension, potent oncology, anti-infectives, central nervous system, and diabetic related diseases, as well as provision of contract research and manufacturing services. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, and Nigeria. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. The company operates as a subsidiary of SRJR Lifesciences LLP.
Research context
Bafna Pharmaceuticals Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the BAFNAPH.NSE discussion.
5 years, 6 months ago
Bafna Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 0.2% above its 200 day moving average.
From a valuation standpoint, the stock is 1.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.7.
Bafna Pharmaceuticals Limited's total revenue rose by 44.4% to $167M since the same quarter in the previous year.
Its net income has increased by 428.8% to $18M since the same quarter in the previous year.
Based on the above factors, Bafna Pharmaceuticals Limited gets an overall score of 4/5.